Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics director-related entities reported open-market sales of common stock. Investment entities associated with Luke Evnin sold a total of 191,762 shares of Werewolf Therapeutics, Inc. common stock in three open-market transactions on May 21, May 22 and May 26, 2026, at reported prices of $0.42, $0.45 and $0.47 per share, respectively. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the entities collectively held 763,685 shares indirectly, spread across several MPM-managed funds and LLCs.
Werewolf Therapeutics, Inc. director Luke Evnin reported three indirect open-market sales of Common Stock by affiliated investment entities. Across May 18–20, 2026, these entities sold a total of 171,049 shares at reported weighted average prices of $0.50, $0.45 and $0.43 per share. The trades were effected under a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the affiliated entities together held 955,447 shares, and Evnin disclaims beneficial ownership beyond his pecuniary interest.